ANTI-DIABETIC COMPOUNDS

The present invention provides a composition of the formula: [FGF21 -1st Linker]-[Ab]- [2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1st linker is covalently attached to th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HUANG, JIE, LEVIN, NANCY JANE, FINN, RORY FRANCIS, BALU, PALANI, LUKSHA, NICHOLAS GARY, MARTIN, JOSEPH PATRICK JR, WASZAK, GREGORY ALLAN, MOSKOWITZ, HAIM, POZZO, MARK JOHN, ANNATHUR, GOPINATH VEDACHALAM, PALANKI, MOORTHY SITHARAMAIAH SURIYANARAYANA, LAURENT, OLIVIER ALEXANDRE, XIE, JIN
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides a composition of the formula: [FGF21 -1st Linker]-[Ab]- [2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.